PTC Therapeutics Inc To Monetize Portion of Risdiplam Royalty Stream For $650 Million From Royalty Pharma PLC Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the PTC To Monetize a Portion of Risdiplam Royalty Stream Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Alex Kane, Investor Relations. Thank you. Please go ahead, sir.
Good morning, and thank you for joining us today to discuss this morning's announcement on the agreement with Royalty Pharma to monetize a portion of the risdiplam royalty stream. A press release with details about this morning's announcement can be found in the Investors section of our corporate website at ptcbio.com.
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Please take a moment to review the posted slide containing our forward-looking statements. Our actual results could materially differ from these forward-looking statements, and such
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |